Tobias Eggert1, Katherine A McGlynn2, Austin Duffy3, Michael P Manns4, Tim F Greten3, Sean F Altekruse5. 1. Gastrointestinal Malignancy Section, Medical Oncology Branch, National Cancer Institute, Bethesda, USA ; Department of Gastroenterology, Hepatology and Endocrinology, School of Medicine, Hannover, Germany. 2. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, USA. 3. Gastrointestinal Malignancy Section, Medical Oncology Branch, National Cancer Institute, Bethesda, USA. 4. Department of Gastroenterology, Hepatology and Endocrinology, School of Medicine, Hannover, Germany. 5. Division of Cancer Control & Population Sciences, National Cancer Institute Rockville, USA.
Abstract
OBJECTIVE: Epidemiological and clinical information on fibrolamellar hepatocellular carcinoma (fHCC) is scarce. We performed a Surveillance, Epidemiology and End Results (SEER) database analysis with the aim of collecting information to better understand the biology and clinical aspects of this rare disease. DESIGN: Incidence trends, race- and age-specific rates, tumor size, first course surgery and five-year relative survival of 191 US cases (SEER) diagnosed with fHCC during 2000-2010 were compared to cases with hepatocellular carcinoma (HCC), HCC-not otherwise specified (HCC-NOS) and other HCC-types. RESULTS: While HCC-NOS incidence rates increased by 5.2% annually from 2000-2008 (p < 0.05) before leveling, the 1.3% change in fHCC incidence was not statistically significant. The rates of fHCC were similar across ethnic groups while HCC-NOS incidence rates were higher among non-whites. Although 16% of fHCC patients had primary tumors ≤5 cm compared to 37% of HCC-NOS cases five-year survival was better among fHCC (34%) than HCC-NOS cases (16%). Fibrolamellar HCC cases of 0-39 years of age were more likely to receive radiofrequency ablation, transplant or resection than HCC-NOS cases of that age. Survival was similar among fibrolamellar and HCC-NOS cases receiving surgery. CONCLUSION: In this largest case series, fibrolamellar and HCC-NOS age- and race-specific incidence rates and time trends differed. Despite larger tumor size than HCC-NOS cases fibrolamellar cases received surgery more often and had better survival rates. Differences in co-morbidity may influence treatment. Studies of fHCC biology, including by age, are recommended.
OBJECTIVE: Epidemiological and clinical information on fibrolamellar hepatocellular carcinoma (fHCC) is scarce. We performed a Surveillance, Epidemiology and End Results (SEER) database analysis with the aim of collecting information to better understand the biology and clinical aspects of this rare disease. DESIGN: Incidence trends, race- and age-specific rates, tumor size, first course surgery and five-year relative survival of 191 US cases (SEER) diagnosed with fHCC during 2000-2010 were compared to cases with hepatocellular carcinoma (HCC), HCC-not otherwise specified (HCC-NOS) and other HCC-types. RESULTS: While HCC-NOS incidence rates increased by 5.2% annually from 2000-2008 (p < 0.05) before leveling, the 1.3% change in fHCC incidence was not statistically significant. The rates of fHCC were similar across ethnic groups while HCC-NOS incidence rates were higher among non-whites. Although 16% of fHCC patients had primary tumors ≤5 cm compared to 37% of HCC-NOS cases five-year survival was better among fHCC (34%) than HCC-NOS cases (16%). Fibrolamellar HCC cases of 0-39 years of age were more likely to receive radiofrequency ablation, transplant or resection than HCC-NOS cases of that age. Survival was similar among fibrolamellar and HCC-NOS cases receiving surgery. CONCLUSION: In this largest case series, fibrolamellar and HCC-NOS age- and race-specific incidence rates and time trends differed. Despite larger tumor size than HCC-NOS cases fibrolamellar cases received surgery more often and had better survival rates. Differences in co-morbidity may influence treatment. Studies of fHCC biology, including by age, are recommended.
Authors: A D Pinna; S Iwatsuki; R G Lee; S Todo; J R Madariaga; J W Marsh; A Casavilla; I Dvorchik; J J Fung; T E Starzl Journal: Hepatology Date: 1997-10 Impact factor: 17.425
Authors: Sanjay Kakar; Lawrence J Burgart; Kenneth P Batts; Joaquin Garcia; Dhanpat Jain; Linda D Ferrell Journal: Mod Pathol Date: 2005-11 Impact factor: 7.842
Authors: Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix Journal: N Engl J Med Date: 2008-07-24 Impact factor: 91.245
Authors: Edward R Kastenhuber; Gadi Lalazar; Shauna L Houlihan; Darjus F Tschaharganeh; Timour Baslan; Chi-Chao Chen; David Requena; Sha Tian; Benedikt Bosbach; John E Wilkinson; Sanford M Simon; Scott W Lowe Journal: Proc Natl Acad Sci U S A Date: 2017-11-21 Impact factor: 11.205
Authors: William J Hammond; Gadi Lalazar; James A Saltsman; Benjamin A Farber; Enrico Danzer; Tshering C Sherpa; Charles D Banda; Jeffrey R Andolina; Sasan Karimi; Cameron W Brennan; Michael S Torbenson; Michael P La Quaglia; Sanford M Simon Journal: Pediatr Blood Cancer Date: 2017-12-29 Impact factor: 3.167
Authors: Suguru Yamashita; Jean-Nicolas Vauthey; Ahmed O Kaseb; Thomas A Aloia; Claudius Conrad; Manal M Hassan; Guillaume Passot; Kanwal P Raghav; Mohamed A Shama; Yun Shin Chun Journal: J Gastrointest Surg Date: 2016-07-25 Impact factor: 3.452
Authors: A G Duffy; S V Ulahannan; L Cao; O E Rahma; O V Makarova-Rusher; D E Kleiner; S Fioravanti; M Walker; S Carey; Y Yu; A M Venkatesan; B Turkbey; P Choyke; J Trepel; K C Bollen; S M Steinberg; W D Figg; T F Greten Journal: United European Gastroenterol J Date: 2015-10 Impact factor: 4.623
Authors: Gadi Lalazar; David Requena; Lavoisier Ramos-Espiritu; Denise Ng; Patrick D Bhola; Ype P de Jong; Ruisi Wang; Nicole J C Narayan; Bassem Shebl; Solomon Levin; Eleftherios Michailidis; Mohammad Kabbani; Koen O A Vercauteren; Arlene M Hurley; Benjamin A Farber; William J Hammond; James A Saltsman; Ethan M Weinberg; J Fraser Glickman; Barbara A Lyons; Jessica Ellison; Erik Schadde; Martin Hertl; Jennifer L Leiting; Mark J Truty; Rory L Smoot; Faith Tierney; Tomoaki Kato; Hans-Guido Wendel; Michael P LaQuaglia; Charles M Rice; Anthony Letai; Philip Coffino; Michael S Torbenson; Michael V Ortiz; Sanford M Simon Journal: Cancer Discov Date: 2021-06-14 Impact factor: 39.397